Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Heshu Sulaiman Rahman¹  Ali Hassanzadeh²  Marwan Mahmood Saleh³  Walid Kamal Abdelbasset⁴  Majid Zamani⁵  Amjad Hussein Altajer⁶  Max Stanley Chartrand⁷  Mostafa Jarahian⁸  Faroogh Marofi⁹  Yashwant Pathak^1,10  Dmitry O. Bokov^1,11  Yoda Yaghoubi^1,12  Mahboubeh Yazdanifar^1,13 

[1] College of Medicine, University of Sulaimani, Sulaymaniyah, Iraq;Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaymaniyah, Iraq;Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Biophysics, College of Applied Sciences, University of Anbar, Ramadi, Iraq;Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia;Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt;Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad University of Medical Sciences, Gonabad, Iran;Department of Pharmaceutics, College of Pharmacy, Almaaqal University, Basra, Iraq;DigiCare Behavioral Research, Casa Grande, AZ, United States;German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany;Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran;Professor and Associate Dean for Faculty Affairs, Taneja College of Pharmacy, University of South Florida, Tampa, FL, United States;Adjunct Professor, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia;Sechenov First Moscow State Medical University, Moscow, Russia;Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States;

关键词: mesenchymal stem/stromal cell;    gene therapy;    chemotherapeutic drug;    oncolytic virus;    cytokine;    pro-drug;   

DOI  :  10.3389/fcell.2021.686453

 received in 2021-03-26, accepted in 2021-06-10,  发布年份 2021

来源: Frontiers

【 摘 要 】

Mesenchymal stem/stromal cell (MSC)-based therapy has become an attractive and advanced scientific research area in the context of cancer therapy. This interest is closely linked to the MSC-marked tropism for tumors, suggesting them as a rational and effective vehicle for drug delivery for both hematological and solid malignancies. Nonetheless, the therapeutic application of the MSCs in human tumors is still controversial because of the induction of several signaling pathways largely contributing to tumor progression and metastasis. In spite of some evidence supporting that MSCs may sustain cancer pathogenesis, increasing proofs have indicated the suppressive influences of MSCs on tumor cells. During the last years, a myriad of preclinical and some clinical studies have been carried out or are ongoing to address the safety and efficacy of the MSC-based delivery of therapeutic agents in diverse types of malignancies. A large number of studies have focused on the MSC application as delivery vehicles for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), chemotherapeutic drug such as gemcitabine (GCB), paclitaxel (PTX), and doxorubicin (DOX), prodrugs such as 5-fluorocytosine (5-FC) and ganciclovir (GCV), and immune cell-activating cytokines along with oncolytic virus. In the current review, we evaluate the latest findings rendering the potential of MSCs to be employed as potent gene/drug delivery vehicle for inducing tumor regression with a special focus on the in vivo reports performed during the last two decades.

【 授权许可】

Unknown   
Copyright © 2021 Hassanzadeh, Altajer, Rahman, Saleh, Bokov, Abdelbasset, Marofi, Zamani, Yaghoubi, Yazdanifar, Pathak, Chartrand and Jarahian.